Hepatitis #C Virus Reactivation Following #COVID-19 Vaccination – A Case Report

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection impacted morbidity and mortality during the pandemic of 2020–2021. A number of anti-COVID-19 vaccines have been developed with an unprecedented speed. While these vaccines have good efficacy and are safe, the experience with their use is limited and hence the knowledge of rare side effects. Identifying rare …

Continue reading Hepatitis #C Virus Reactivation Following #COVID-19 Vaccination – A Case Report

#Elastography is unable to exclude #cirrhosis after sustained virological response in #HCV-infected patients with advanced chronic liver disease

Liver fibrosis and transient elastography (TE) correlation in hepatitis C virus (HCV)-infected patients with compensated advanced chronic liver disease (cACLD) after sustained virological response (SVR) is unknown. AimsTo evaluate TE accuracy at identifying cirrhosis 3 years after HCV-eradication. MethodsProspective, multi-centric study including HCV-cACLD patients before direct-acting antivirals (DAA). Diagnostic accuracy of TE (area under ROC, …

Continue reading #Elastography is unable to exclude #cirrhosis after sustained virological response in #HCV-infected patients with advanced chronic liver disease

#Fibrosis improvement in patients with #HCV treated with direct-acting antivirals

More prospective studies are needed to characterize fibrosis improvement in patients with hepatitis C virus (HCV) who are treated with direct-acting antivirals (DAAs). The aims of this study were to assess changes in elastography scores from baseline to 1-year follow-up in patients with HCV, to identify factors that were independently associated with improvement in fibrosis …

Continue reading #Fibrosis improvement in patients with #HCV treated with direct-acting antivirals

Is an 8‐week regimen of glecaprevir/pibrentasvir sufficient for all #hepatitis C virus infected patients in the real‐world experience?

The revolution of the antiviral treatment of hepatitis C virus (HCV) infection resulting in higher effectiveness came with the introduction of direct‐acting antivirals with pangenotypic regimens as a final touch. Among them, the combination of glecaprevir (GLE) and pibrentasvir (PIB) provides the opportunity for shortening therapy to 8 weeks in the majority of patients. Because …

Continue reading Is an 8‐week regimen of glecaprevir/pibrentasvir sufficient for all #hepatitis C virus infected patients in the real‐world experience?

GES: A validated simple score to predict the risk of #HCC in patients with #HCV‐GT4‐associated advanced liver fibrosis after oral antivirals

Hepatocellular carcinoma (HCC) risk persists after hepatitis C virus (HCV) eradication with direct‐acting antivirals (DAAs), particularly in patients with cirrhosis. Identifying those who are likely to develop HCC is a critical unmet medical need. Our aim is to develop a score that offers individualized patient HCC risk prediction.. ..In the derivation cohort, the median follow‐up …

Continue reading GES: A validated simple score to predict the risk of #HCC in patients with #HCV‐GT4‐associated advanced liver fibrosis after oral antivirals